IL235066A0 - Sorcs1 for use in the treatment of obesity and overweight - Google Patents

Sorcs1 for use in the treatment of obesity and overweight

Info

Publication number
IL235066A0
IL235066A0 IL235066A IL23506614A IL235066A0 IL 235066 A0 IL235066 A0 IL 235066A0 IL 235066 A IL235066 A IL 235066A IL 23506614 A IL23506614 A IL 23506614A IL 235066 A0 IL235066 A0 IL 235066A0
Authority
IL
Israel
Prior art keywords
sorcs1
overweight
obesity
treatment
Prior art date
Application number
IL235066A
Other languages
English (en)
Hebrew (he)
Inventor
Karen-Marie Pedersen
Anders Nykj/Er
Mads Fuglsang Kjolby
Original Assignee
Univ Aarhus
Pedersen Karen Marie
Anders Nykj/Er
Mads Fuglsang Kjolby
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aarhus, Pedersen Karen Marie, Anders Nykj/Er, Mads Fuglsang Kjolby filed Critical Univ Aarhus
Publication of IL235066A0 publication Critical patent/IL235066A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL235066A 2012-04-17 2014-10-07 Sorcs1 for use in the treatment of obesity and overweight IL235066A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201270191 2012-04-17
PCT/DK2013/050107 WO2013156031A2 (en) 2012-04-17 2013-04-17 SorCS1 FOR USE IN THE TREATMENT OF OBESITY AND OVERWEIGHT

Publications (1)

Publication Number Publication Date
IL235066A0 true IL235066A0 (en) 2014-12-31

Family

ID=49384162

Family Applications (1)

Application Number Title Priority Date Filing Date
IL235066A IL235066A0 (en) 2012-04-17 2014-10-07 Sorcs1 for use in the treatment of obesity and overweight

Country Status (10)

Country Link
US (1) US20150166629A1 (https=)
EP (1) EP2874646A4 (https=)
JP (1) JP2015514726A (https=)
CN (1) CN104470532A (https=)
AU (1) AU2013248727A1 (https=)
CA (1) CA2870211A1 (https=)
HK (1) HK1208159A1 (https=)
IL (1) IL235066A0 (https=)
SG (1) SG11201406455YA (https=)
WO (1) WO2013156031A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105136781B (zh) * 2015-08-13 2018-03-30 上海交通大学医学院附属瑞金医院 脂肪因子grem2作为药物靶点在治疗肥胖症药物中的应用
EP3666281A1 (en) * 2018-12-14 2020-06-17 Insusense ApS Compositions comprising sortilin-1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223392A (en) * 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
AT404357B (de) * 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
KR100773323B1 (ko) * 2000-01-10 2007-11-05 맥시겐 홀딩스 리미티드 지-씨에스에프 접합체
CA2498476A1 (en) * 2002-09-09 2004-03-18 Wisconsin Alumni Research Foundation Type 2 diabetes susceptibility genes
RS60019B1 (sr) * 2006-12-21 2020-04-30 H Lundbeck As Modulacija aktivnosti proneurotrofina
EP2008666A1 (en) * 2007-06-29 2008-12-31 Institut Pasteur Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications
EP2440233B1 (en) * 2009-06-10 2016-07-13 Aarhus Universitet Sorcs1-like agent for use in the treatment of insulin resistance and diseases related thereto

Also Published As

Publication number Publication date
WO2013156031A3 (en) 2013-12-12
EP2874646A4 (en) 2016-07-06
EP2874646A2 (en) 2015-05-27
CN104470532A (zh) 2015-03-25
JP2015514726A (ja) 2015-05-21
AU2013248727A1 (en) 2014-11-06
WO2013156031A2 (en) 2013-10-24
HK1208159A1 (en) 2016-02-26
US20150166629A1 (en) 2015-06-18
CA2870211A1 (en) 2013-10-24
SG11201406455YA (en) 2014-11-27

Similar Documents

Publication Publication Date Title
IL282128A (en) Methods of treating overweight and obesity
GB2478595B (en) Phytocannabinoids in the treatment of glioma
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
GB201120993D0 (en) Novel compounds and their use in therapy
IL237125A0 (en) Use of preparations containing niclosamide and/or its derivatives for the treatment of solid tumors
IL238027A0 (en) 2-phenyl-5-heterocyclyl-tetrahydro-h2-pyran-3-amine compounds for use in the treatment of diabetes and related disorders
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
IL229381B (en) Brilacitidine and its results for use in the treatment of mucositis
PL2900230T3 (pl) Związki do leczenia otyłości i sposoby ich zastosowania
EP2922536A4 (en) USE OF BUCILLAMINE IN THE TREATMENT OF GOUTTE
ZA201501503B (en) Bio-inoculant and use thereof for treatment of effluents
EP2896294A4 (en) MICRORNA IN HUMAN MILK AND USE THEREOF
IL238126B (en) Compositions for the treatment and prevention of obesity
IL233875A0 (en) A preparation and its use for the treatment of anal fissures
LT2845598T (lt) Preparatas, skirtas naudoti netipinės osteoporozės prevencijai ir gydymui
ZA201401800B (en) Novel plant defensins and use in the treatment of proliferative diseases
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
IL233080B (en) Bisarylsulfonamides used to treat inflammation and cancer
PL2872176T3 (pl) Karboranyloporfiryny do stosowania w leczeniu raka
ZA201503266B (en) Pyidone derivatives and uses thereof in the treatment of tuberculosis
IL235066A0 (en) Sorcs1 for use in the treatment of obesity and overweight
SI2663185T1 (sl) Calebin A za uporabo pri zdravljenju vnetja in debelosti
LT2863932T (lt) Kompozicija, skirta naudoti limfedemos gydymui
EP2934699A4 (en) PLOD2 GENE STIMULATORS AND USE OF SAID STIMULATORS FOR TREATING SKIN
PT2389936E (pt) Aminaftona para utilização no tratamento e/ou prevenção de enxaqueca